SynthesisBMC infectious diseases2025
Immunology of vector-borne diseases: the role of immunopharmacology in controlling viral and parasitic infections.
Synthesis in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Global epidemiology and evolutionary dynamics of arboviruses: A systematic review of surveillance, control strategies, and emerging threats.Dialogues in health · 2026Review
- Investigation of chikungunya arbovirus in cities of Bushehr province: An ELISA-based cross-sectional study.Virus research · 2026Article
- Early immunogenic response to intradermal, subcutaneous, and intramuscular rabies vaccination in cattle and buffaloes: a field study.Tropical animal health and production · 2026Article
- Melanin biosynthesis and functional roles in insects: insights into immunological defense, physiological regulation, and environmental adaptation.Annals of medicine and surgery (2012) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVector-borne diseases (VBDs) pose a significant global health threat, driven by complex interactions between pathogens, vectors, and host immune responses. Understanding the immunopharmacological mechanisms underlying these interactions is crucial for developing novel therapeutic and preventive strategies. This review explores the immunomodulatory effects of vector saliva, pathogen-induced immune evasion, and host-directed immunotherapies to provide a comprehensive perspective on immune regulation in VBDs.
methodsA systematic review of peer-reviewed literature was conducted using databases such as PubMed, Scopus, and Web of Science. Studies on host immune responses, vector-mediated immunomodulation, and immunopharmacological interventions were included. Key themes were synthesized to highlight emerging therapeutic approaches, including monoclonal antibodies, immune checkpoint inhibitors, and vector-targeted vaccines.
resultsThe findings reveal that vector saliva modulates innate and adaptive immunity, altering disease outcomes. Pathogens exploit immune checkpoints to evade host defenses, necessitating targeted immunomodulatory therapies. Advances in monoclonal antibodies, metabolic reprogramming, and microbiome-based interventions offer promising avenues for disease control. DISCUSSION: Future research should integrate systems immunology, AI-driven predictive models, and microbiome-targeted strategies to enhance immunotherapeutic efficacy. Ethical and regulatory challenges must also be addressed to ensure equitable implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.